Apyx Medical Corporation
BVX
NASDAQ Global Select6.48
USD
-0.01
- -
Apyx Medical Corporation
BVX
(NASDAQ Global Select)
Recent
price
6.48
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Apyx Medical Corporation (Nasdaq: APYX), an advanced energy technology company, designs, develops, manufactures and markets innovative electrosurgical equipment and medical devices for surgical and cosmetic procedures in the United States and internationally. The company operates through two segments, Advanced Energy and Original Equipment Manufacturer (OEM); the Advanced Energy segment offers helium plasma technology products marketed as Renuvion for cosmetic surgery applications, providing plastic surgeons, facial plastic surgeons and cosmetic physicians with controlled subdermal tissue heating to achieve skin tightening and body contouring results, and as J-Plasma for hospital surgical markets, enabling precise cutting, coagulation and ablation of soft tissue during open and minimally invasive procedures using a helium plasma generator, single-use handpieces and helium gas accessories; the OEM segment produces electrosurgical generators, medical devices and related accessories for third-party medical device manufacturers and start-ups. Apyx Medical, formerly Bovie Medical Corporation, was founded in 1982 and is headquartered in Clearwater, Florida, with a manufacturing facility in Bulgaria serving as its European authorized service center. The company recently launched commercial U.S. sales of the AYON Body Contouring System, the industry's first all-in-one surgical platform integrating Renuvion helium plasma technology with monopolar and bipolar energy, adaptive touch screens, procedural presets and power liposuction capabilities following FDA 510(k) clearance in May 2025 and a label expansion submission in October 2025; initiated Renuvion distribution in China through a partnership with GlamMoon Medical Technology in July 2025; appointed key sales executives in August 2025 to drive global expansion of Renuvion and AYON; raised full-year 2025 revenue guidance to $50.5 million-$52.5 million; and completed a $10 million public offering of common stock in November 2025.
Company News
Bovie Medical (NYSEAMERICAN:BVX) Stock Passes Below 50 Day Moving Average – What’s Next?
Bovie Medical (NYSEAMERICAN:BVX) Stock Passes Below 200-Day Moving Average – Time to Sell?
CME Is Launching a Bitcoin VIX: Here's Why That Changes Wall Street's Bitcoin Game
Bovie Medical (NYSEAMERICAN:BVX) Stock Price Passes Above Fifty Day Moving Average – What’s Next?
Bovie Medical (NYSEAMERICAN:BVX) Stock Passes Below 50-Day Moving Average – Here’s Why
Bovie Medical (NYSEAMERICAN:BVX) Share Price Passes Below Fifty Day Moving Average – Should You Sell?